Codelivery of Salinomycin and Doxorubicin Using Nanoliposomes for Targeting Both Liver Cancer Cells and Cancer Stem Cells

Gong, Zhirong; Chen, Dazhong; Xie, Fang; Liu, Junjie; He, Zhiguo; Zou, Hao; Yuan, Yu; Cao, Yan; Sun, Zhiguo; Xinxia, Wang; Hai, Zhang; Yin, Chuan; Gao, Jie; Zhong, Yanqiang; Lü, Ying

doi:10.2217/nnm-2016-0137

Cited by 44 publications

(45 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD133, ring finger protein 5, smoothened, frizzled class receptor, POU class 5 homeobox 1, NANOG and c-MYC were revealed to be significantly increased in CD133 + cells compared with CD133 -cells (P<0.05). The tumor sphere formation ability represents the self-renewal capability of CSCs (11,12). As presented in Fig.…”

Section: Cd133 + Ovarian Cancer Cells Possess the Properties Of Ovarianmentioning

confidence: 99%

See 1 more Smart Citation

The enhanced delivery of salinomycin to CD133+ ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles

Huang

Deng

2018

Oncol Lett

View full text Add to dashboard Cite

Abstract. Ovarian cancer is the most lethal gynecologic malignancy, and ovarian cancer stem cells (CSCs) serve a pivotal function in the metastasis and recurrence of ovarian cancer. Multiple previous studies have validated CD133 as a marker of ovarian CSCs. Although salinomycin is a promising therapeutic agent that has been demonstrated to kill CSCs in various types of cancer, poor aqueous solubility hampers its clinical application. The present study used salinomycin-loaded poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles conjugated with CD133 antibodies (CD133-SAL-NP) to eliminate CD133 + ovarian CSCs. The results revealed that CD133-SAL-NPs were of an appropriate size (149.2 nm) and exhibited sustained drug release. CD133-SAL-NPs efficiently bound to CD133 + ovarian cancer cells, resulting in an increased cytotoxic effect in CD133 + ovarian cancer cells, compared with the untargeted SAL-NPs and salinomycin. CD133-SAL-NPs reduced the percentage of CD133 + ovarian CSCs in ovarian cells more effectively than treatment with salinomycin or SAL-NPs, suggesting that CD133-SAL-NP targeted CD133 + ovarian CSCs. In nude mice bearing ovarian cancer xenografts, CD133-SAL-NPs exerted improved therapeutic effects compared with SAL-NPs and salinomycin. Thus, CD133 was demonstrated to be a promising target for drug delivery to ovarian CSCs, and may be useful as an agent to inhibit the growth of ovarian cancer by targeting CD133 + ovarian CSCs. CD133-SAL-NPs may therefore represent a promising approach for the treatment of ovarian cancer.

show abstract

Section: Cd133 + Ovarian Cancer Cells Possess the Properties Of Ovarianmentioning

confidence: 99%

“…Owing to its poor water solubility, salinomycin must be dissolved in ethanol prior to administration (11,12). Nanoparticles have emerged as a promising approach to improve the solubility of salinomycin (5,6).…”

Section: Introductionmentioning

confidence: 99%

The enhanced delivery of salinomycin to CD133+ ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles

Huang

Deng

2018

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Numerous studies have proposed that differentiated cancer cells have the ability to be converted into CICs (7)(8)(9). To obtain improved cancer therapeutic efficacy, several combination strategies that target both CICs and non-CICs have recently been developed (10,11). Gong et al developed salinomycin sodium (SS) and doxorubicin-loaded liposomes to eliminate both liver CICs and cancer cells, and demonstrated that this combination therapy is superior to single therapy with SS or doxorubicin (10).…”

Section: Introductionmentioning

confidence: 99%

Promoted delivery of salinomycin sodium to lung cancer cells by dual targeting PLGA hybrid nanoparticles

Zhou

Sun²,

Chen

et al. 2018

Int J Oncol

View full text Add to dashboard Cite

As the leading cause of cancer-associated mortality worldwide, lung cancer is often associated with therapy failure and decreases in survival; these factors are often attributed to lung cancer-initiating cells (CICs). In addition, sufficient evidence has suggested that simultaneous targeting of CICs, together with cancer cells, is critical for the achievement of preferable therapeutic efficacy, due to the spontaneous conversion between CICs and cancer cells. Salinomycin sodium (SS) is an antibacterial therapeutic agent that exerts potent activity against CICs in various types of cancer, including lung cancer. The present study generated SS lipid-polymer hybrid nanoparticles (NPs) with cluster of differentiation (CD)133 and epidermal growth factor receptor (EGFR) antibodies (CD133/EGFR SS NPs) for the simultaneous treatment of lung CICs and cancer cells. The activity of CD133/EGFR SS NPs was analyzed using cytotoxicity and tumorsphere formation assays, flow cytometry, and an in vivo anticancer assay in mice bearing lung cancer xenografts. The results revealed that CD133/EGFR SS NPs effectively promoted SS delivery to lung CICs and cancer cells, achieving superior therapeutic effects compared with non-targeted NPs or NPs with a single antibody. Furthermore, CD133/EGFR SS NPs exhibited the best efficacy in inhibiting tumor growth compared with the control agents in lung cancer-bearing mice. In conclusion, CD133/EGFR SS NPs may be capable of efficiently targeting and treating lung CICs together with cancer cells, and may represent an effective treatment for lung cancer.

show abstract

“…Furthermore, our group loaded SAL and DOX into liposomes separately, and in combination, to assess the subsequent antitumor activity in liver cancer. The results showed that co-delivery liposomes and separate liposomes had similar antitumor activity [36].…”

Section: Liposome-mediated Combined Chemotherapymentioning

confidence: 95%

Nanomedicine-Mediated Combination Drug Therapy in Tumor

Chen¹,

Xie²,

Sun³

et al. 2017

PHARMSCI

Self Cite

View full text Add to dashboard Cite

Background:Combined chemotherapy has gradually become one of the conventional methods of cancer treatment due to the limitation of monotherapy. However, combined chemotherapy has several drawbacks that may lead to treatment failure because drug synergy cannot be guaranteed, achievement of the optimal synergistic drug ratio is difficult, and drug uptake into the tumor is inconsistent. Nanomedicine can be a safe and effective form of drug delivery, which may address the problems associated with combination chemotherapy. Objective:This review summarizes the recent research in this area, including the use of nanoparticles, liposomes, lipid-polymer hybrid nanoparticles, and polymeric micelles, and provides new approach for combined chemotherapy. Methods:By collecting and referring to the related literature in recent years. Results:Compared with conventional drugs, nanomedicine has the following advantages: it increases bioavailability of poorly soluble drugs, prolongs drug circulation time in vivo, and permits multiple drug loading, all of which could improve drug efficacy and reduce toxicity. Furthermore, nanomedicine can maintain the synergistic ratio of the drugs; deliver the drugs to the tumor at the same time, such that two or more drugs of tumor treatment achieve synchronization in time and space; and alter the pharmacokinetics and distribution profile in vivo such that these are dependent on nanocarrier properties (rather than being dependent on the drugs themselves). Conclusion:Therefore, nanomedicine-mediated combination drug therapy is promising in the treatment of tumors.

show abstract

Codelivery of Salinomycin and Doxorubicin Using Nanoliposomes for Targeting Both Liver Cancer Cells and Cancer Stem Cells

Cited by 44 publications

References 30 publications

The enhanced delivery of salinomycin to CD133+ ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles

The enhanced delivery of salinomycin to CD133+ ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles

Promoted delivery of salinomycin sodium to lung cancer cells by dual targeting PLGA hybrid nanoparticles

Nanomedicine-Mediated Combination Drug Therapy in Tumor

Contact Info

Product

Resources

About